128 related articles for article (PubMed ID: 2230875)
1. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.
Stewart CF; Arbuck SG; Fleming RA; Evans WE
J Clin Oncol; 1990 Nov; 8(11):1874-9. PubMed ID: 2230875
[TBL] [Abstract][Full Text] [Related]
2. Etoposide pharmacokinetics in patients with normal and abnormal organ function.
Arbuck SG; Douglass HO; Crom WR; Goodwin P; Silk Y; Cooper C; Evans WE
J Clin Oncol; 1986 Nov; 4(11):1690-5. PubMed ID: 3772420
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
[TBL] [Abstract][Full Text] [Related]
4. Disposition of total and unbound etoposide following high-dose therapy.
Schwinghammer TL; Fleming RA; Rosenfeld CS; Przepiorka D; Shadduck RK; Bloom EJ; Stewart CF
Cancer Chemother Pharmacol; 1993; 32(4):273-8. PubMed ID: 8324869
[TBL] [Abstract][Full Text] [Related]
5. Predicting etoposide toxicity: relationship to organ function and protein binding.
Joel SP; Shah R; Clark PI; Slevin ML
J Clin Oncol; 1996 Jan; 14(1):257-67. PubMed ID: 8558207
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients.
Stewart CF; Fleming RA; Arbuck SG; Evans WE
Cancer Res; 1990 Nov; 50(21):6854-6. PubMed ID: 2208152
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of total and unbound etoposide.
Nguyen L; Chatelut E; Chevreau C; Tranchand B; Lochon I; Bachaud JM; Pujol A; Houin G; Bugat R; Canal P
Cancer Chemother Pharmacol; 1998; 41(2):125-32. PubMed ID: 9443625
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
[TBL] [Abstract][Full Text] [Related]
9. Relation of systemic exposure to unbound etoposide and hematologic toxicity.
Stewart CF; Arbuck SG; Fleming RA; Evans WE
Clin Pharmacol Ther; 1991 Oct; 50(4):385-93. PubMed ID: 1914374
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of an etoposide infused over three days: concomitant infusion with cisplatin.
Minami H; Horio Y; Sakai S; Saka H; Shimokata K
Jpn J Clin Oncol; 1991 Dec; 21(6):400-5. PubMed ID: 1666659
[TBL] [Abstract][Full Text] [Related]
11. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
[TBL] [Abstract][Full Text] [Related]
12. Altered protein binding of etoposide in patients with cancer.
Stewart CF; Pieper JA; Arbuck SG; Evans WE
Clin Pharmacol Ther; 1989 Jan; 45(1):49-55. PubMed ID: 2910637
[TBL] [Abstract][Full Text] [Related]
13. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
14. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule.
Perdaems N; Bachaud JM; Rouzaud P; Murris-Espin M; Hermant C; Mihura J; Lochon I; Houin G; Canal P; Chatelut E
Eur J Clin Pharmacol; 1998; 54(9-10):677-83. PubMed ID: 9923567
[TBL] [Abstract][Full Text] [Related]
15. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin.
Relling MV; McLeod HL; Bowman LC; Santana VM
Clin Pharmacol Ther; 1994 Nov; 56(5):503-11. PubMed ID: 7955814
[TBL] [Abstract][Full Text] [Related]
16. Etoposide kinetics in patients with obstructive jaundice.
Hande KR; Wolff SN; Greco FA; Hainsworth JD; Reed G; Johnson DH
J Clin Oncol; 1990 Jun; 8(6):1101-7. PubMed ID: 2348225
[TBL] [Abstract][Full Text] [Related]
17. Relationship of systemic exposure to unbound docetaxel and neutropenia.
Baker SD; Li J; ten Tije AJ; Figg WD; Graveland W; Verweij J; Sparreboom A
Clin Pharmacol Ther; 2005 Jan; 77(1):43-53. PubMed ID: 15637530
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetic aspects of oral administration of etoposide].
Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
[TBL] [Abstract][Full Text] [Related]
19. Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion.
van Tellingen O; Kuck MT; Vlasveld LT; Rodenhuis S; Nooijen WJ; Beijnen JH
Cancer Chemother Pharmacol; 1996; 38(4):387-90. PubMed ID: 8674164
[TBL] [Abstract][Full Text] [Related]
20. Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
You B; Salles G; Bachy E; Casasnovas O; Tilly H; Ribrag V; Sebban C; Hénin E; Guitton J; Tod M; Freyer G
Cancer Chemother Pharmacol; 2015 Nov; 76(5):939-48. PubMed ID: 26391155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
